2021
DOI: 10.1111/cei.13620
|View full text |Cite
|
Sign up to set email alerts
|

Lymphadenopathy at the crossroad between immunodeficiency and autoinflammation: An intriguing challenge

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
25
0
2

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 19 publications
(28 citation statements)
references
References 110 publications
(189 reference statements)
1
25
0
2
Order By: Relevance
“…In our study group showing lymphoproliferative disorders, the clinical diagnoses included lymphadenopathy, GLILD (as shown in Figure 6 ), hepatosplenomegaly, and cutaneous granulomas. It is worth noting that, in all our patients with CVID presenting with GLILD, other extrapulmonary, systemic features of immune dysregulation have been observed, in the form of lymphadenopathy, granulomatous liver and spleen disease, and cutaneous granulomatosis, supporting the hypothesis of the generalized nature of the granulomatous disease in CVID ( 9 , 10 , 42 , 43 ). It is also worth pointing out that, in our patients with pediatric CVID, same as in children with autoimmune cytopenias reported in ( 36 ), either GLILD or any other granulomatous lymphoproliferative manifestations were not associated with increased numbers of immature B-cell subset with CD19+CD21lo immunophenotype, in which expansion has been hypothesized to be a predictor of granulomatous complications in CVID ( 8 , 44 , 45 ).…”
Section: Discussionsupporting
confidence: 80%
“…In our study group showing lymphoproliferative disorders, the clinical diagnoses included lymphadenopathy, GLILD (as shown in Figure 6 ), hepatosplenomegaly, and cutaneous granulomas. It is worth noting that, in all our patients with CVID presenting with GLILD, other extrapulmonary, systemic features of immune dysregulation have been observed, in the form of lymphadenopathy, granulomatous liver and spleen disease, and cutaneous granulomatosis, supporting the hypothesis of the generalized nature of the granulomatous disease in CVID ( 9 , 10 , 42 , 43 ). It is also worth pointing out that, in our patients with pediatric CVID, same as in children with autoimmune cytopenias reported in ( 36 ), either GLILD or any other granulomatous lymphoproliferative manifestations were not associated with increased numbers of immature B-cell subset with CD19+CD21lo immunophenotype, in which expansion has been hypothesized to be a predictor of granulomatous complications in CVID ( 8 , 44 , 45 ).…”
Section: Discussionsupporting
confidence: 80%
“…Clinically, this often presents as generalized lymphadenopathy and splenomegaly. The challenge is to differentiate it from lymphoma [ 5 ]. In 20% of patients with a CVID-like phenotype, monogenic defects responsible for immune deregulation have been identified.…”
Section: Introductionmentioning
confidence: 99%
“…Clinical symptoms are non-specific and mimic those of an infection, inflammation, or neoplasia. The clinical features are characterized by chronic or recurrent lymphadenopathy, hepatosplenomegaly, extranodal infiltration, and/or peripheral blood lymphocytosis ( 4 ). In certain immune disorders such as autoimmune lymphoproliferative syndrome (ALPS) and X-linked lymphoproliferation (XLP), LP is the predominant feature at disease onset.…”
Section: Clinical Issuesmentioning
confidence: 99%